JP2022500079A5 - - Google Patents
Info
- Publication number
- JP2022500079A5 JP2022500079A5 JP2021538176A JP2021538176A JP2022500079A5 JP 2022500079 A5 JP2022500079 A5 JP 2022500079A5 JP 2021538176 A JP2021538176 A JP 2021538176A JP 2021538176 A JP2021538176 A JP 2021538176A JP 2022500079 A5 JP2022500079 A5 JP 2022500079A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- modified
- oligomer compound
- modified oligonucleotide
- compound according
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729067P | 2018-09-10 | 2018-09-10 | |
| US62/729,067 | 2018-09-10 | ||
| US201962891127P | 2019-08-23 | 2019-08-23 | |
| US62/891,127 | 2019-08-23 | ||
| PCT/US2019/050476 WO2020055917A1 (en) | 2018-09-10 | 2019-09-10 | Compounds and methods for modulating cln3 expression |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500079A JP2022500079A (ja) | 2022-01-04 |
| JP2022500079A5 true JP2022500079A5 (https=) | 2022-09-21 |
| JPWO2020055917A5 JPWO2020055917A5 (https=) | 2022-09-21 |
| JP7511563B2 JP7511563B2 (ja) | 2024-07-05 |
Family
ID=69777155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538176A Active JP7511563B2 (ja) | 2018-09-10 | 2019-09-10 | Ｃｌｎ３の発現を調節するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220280545A1 (https=) |
| EP (1) | EP3849564A4 (https=) |
| JP (1) | JP7511563B2 (https=) |
| WO (1) | WO2020055917A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091693A1 (ru) | 2018-01-12 | 2021-04-14 | Бристол-Маерс Сквибб Компани | Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения |
| BR112020013994A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos |
| WO2022150369A1 (en) * | 2021-01-06 | 2022-07-14 | Exicure Operating Company | Compounds for the treatment of batten disease |
| WO2025091028A1 (en) * | 2023-10-27 | 2025-05-01 | The Regents Of The University Of Michigan | Compounds and methods for modulating cln3 expression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US7314750B2 (en) * | 2002-11-20 | 2008-01-01 | Affymetrix, Inc. | Addressable oligonucleotide array of the rat genome |
| EP2285961A4 (en) * | 2008-05-15 | 2012-10-17 | Topigen Pharmaceuticals Inc | OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION |
| JP2014054185A (ja) | 2011-01-12 | 2014-03-27 | Astellas Pharma Inc | 新規ｂｒａｆ融合体の検出法 |
| EP4166667A3 (en) * | 2013-10-11 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| ES2797679T3 (es) * | 2013-12-02 | 2020-12-03 | Ionis Pharmaceuticals Inc | Compuestos antisentido y usos de los mismos |
| AU2015311704B2 (en) * | 2014-09-07 | 2021-12-09 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| WO2016061263A1 (en) * | 2014-10-14 | 2016-04-21 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| FI3386518T3 (fi) * | 2015-12-07 | 2025-09-25 | Genzyme Corp | Menetelmiä ja koostumuksia serpinc1:een liittyvän häiriön hoitamiseksi |
| WO2022150369A1 (en) * | 2021-01-06 | 2022-07-14 | Exicure Operating Company | Compounds for the treatment of batten disease |
-
2019
- 2019-09-10 JP JP2021538176A patent/JP7511563B2/ja active Active
- 2019-09-10 EP EP19859762.7A patent/EP3849564A4/en active Pending
- 2019-09-10 US US17/274,981 patent/US20220280545A1/en active Pending
- 2019-09-10 WO PCT/US2019/050476 patent/WO2020055917A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500079A5 (https=) | ||
| JP7049249B2 (ja) | 中枢神経系疾患の処置のための組成物および方法 | |
| JP7342169B2 (ja) | 酸性アルファ－グルコシダーゼ遺伝子に関連する疾患を処置するためのアンチセンスオリゴマーおよびそれを用いる方法 | |
| TWI736514B (zh) | 酸性α葡萄糖苷酶之反義股誘導之外顯子２包含 | |
| JP7129702B2 (ja) | オーバーハングを有する二本鎖核酸複合体 | |
| JP2635216B2 (ja) | プロテインキナーゼｃのオリゴヌクレオチド調節 | |
| JP5559159B2 (ja) | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 | |
| JP2016513976A5 (https=) | ||
| CA2357950C (en) | Therapeutic phosphodiesterase inhibitors | |
| US8618073B2 (en) | Use of miR-29 for cell protection | |
| TW202400792A (zh) | 用於抑制ｍａｐｔ表現之組合物及方法 | |
| JPH09503512A (ja) | ニューロンの生き残りを増加させる方法およびそれに有用な薬剤 | |
| JPWO2020106996A5 (https=) | ||
| KR20110055693A (ko) | 트랜스펙션제 | |
| JP2023548658A (ja) | グリア細胞へのオリゴヌクレオチドの選択的送達 | |
| US10918657B2 (en) | Treatment of spinal cord injury or traumatic brain injury by inhibition of synuclein protein aggregation | |
| JPWO2020055917A5 (https=) | ||
| JP2023513188A (ja) | 遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤 | |
| EP4499111A2 (en) | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases | |
| JPWO2022026589A5 (https=) | ||
| US20250034569A1 (en) | Antisense oligonucleotide drug targets | |
| US10415039B2 (en) | Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof | |
| JP7851349B2 (ja) | Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド | |
| WO2025063185A1 (ja) | １本鎖ポリヌクレオチド | |
| WO2025136934A1 (en) | Compositions and methods for modulating sptlc2 |